Login Register Cart 0
Case Report

Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer

Author(s): Hui Qu, Yu Xia and Xiuqin Li *

Volume 20, Issue 4, 2020

Page: [313 - 320] Pages: 8

DOI: 10.2174/1566523220666200826100245

Price: $65

Abstract

Background: High-grade serous ovarian carcinoma (HGSOC) is one of the most common ovarian epithelial carcinomas. It is highly invasive, easily recurs after systemic treatment, and has a poor prognosis. Despite many new chemotherapeutic drugs and trials of combinations of different regimens that have been used in treatment attempts, there has been no meaningful progress in the treatment of HGSOC. With the development of gene sequencing technology, gene therapy has become a new direction for tumors treatment. It is reported that the P53 has a very high mutation rate in HGSOC, which provides a theoretical basis for the application of gene therapy in HGSOC patients. Recombinant human p53 adenovirus injection (rAd-p53) is the world's first approved oncology gene therapy drug.

Case Report: In this article, we retrospectively analyzed 4 cases of HGSOC patients treated with rAdp53. Three of them were recurrent ovarian cancer, and one was the initial treatment. The treatment method was to apply recombinant human p53 adenovirus injection (rAd-p53) to the lesions for local injection, 72 hours later, the lesions were injected with bleomycin or fluorouracil, and systemic intravenous chemotherapy was performed simultaneously. After rAd-p53 treatment, one of the three relapsed ovarian cancers achieved complete remission(CR), one achieved partial remission (PR), and one was stable disease (SD); the treatment-naive patient was operated after rAd-p53 combined with neoadjuvant chemotherapy and achieved pathological CR. Under the action of various mechanisms of P53, the subsequent tumor treatment showed the characteristics of slow tumor progression, no ascites, and local recurrence. As of the end of follow-up, the OS of 4 patients was 71-120 months.

Conclusion: Through the remarkable efficacy of these 4 cases, we can see that the application of rAdp53 combined with chemotherapy can effectively control tumor lesions, prolong the survival time of patients, improve the quality of life of patients, which provide valuable experiences for rAd-p53 treatment in ovarian cancer, promote the further development and progress of gene therapy in this field.

Keywords: High-grade serous ovarian carcinoma, HGSOC, rAd-p53, gene therapy, tumor cells, epithelial ovarian carcinoma.

« Previous
Graphical Abstract

[1]
Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164(5): 1511-8.
[http://dx.doi.org/10.1016/S0002-9440(10)63708-X] [PMID: 15111296]
[2]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86.
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[3]
Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010; 10(11): 803-8.
[http://dx.doi.org/10.1038/nrc2946] [PMID: 20944665]
[4]
Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010; 221(1): 49-56.
[http://dx.doi.org/10.1002/path.2696] [PMID: 20229506]
[5]
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474(7353): 609-15.
[http://dx.doi.org/10.1038/nature10166] [PMID: 21720365]
[6]
Hayano T, Yokota Y, Hosomichi K, et al. Molecular characterization of an intact p53 pathway subtype in high-grade serous ovarian cancer. PLoS One 2014; 9(12)e114491
[http://dx.doi.org/10.1371/journal.pone.0114491] [PMID: 25460179]
[7]
Zhong F, Zhu T, Pan X, et al. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53. Cancer Med 2019; 8(8): 3928-35.
[http://dx.doi.org/10.1002/cam4.2243] [PMID: 31124283]
[8]
Ma WS, Ma JG, Xing LN. Efficacy and safety of recombinant human adenovirus p53 combined with chemoradiotherapy in the treatment of recurrent nasopharyngeal carcinoma. Anticancer Drugs 2017; 28(2): 230-6.
[http://dx.doi.org/10.1097/CAD.0000000000000448] [PMID: 27775992]
[9]
Pan JJ, Zhang SW, Chen CB, et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27(5): 799-804.
[http://dx.doi.org/10.1200/JCO.2008.18.9670] [PMID: 19103729]
[10]
Wang J, Wang X, Yang J, et al. Treatment of local advanced non-small cell lung cancer with recombinant human p53adenovirus combined with radiochemotherapy. J Guiyang Med Coll 2014; 39: 225-8.
[11]
Ning X, Sun Z, Wang Y, et al. Docetaxel plus trans-tracheal injection of adenoviral-mediated p53 versus docetaxel alone in patients with previously treated non-small-cell lung cancer. Cancer Gene Ther 2011; 18(6): 444-9.
[http://dx.doi.org/10.1038/cgt.2011.15] [PMID: 21455255]
[12]
Xu Z, Quan X, Jiang J. Clinical observations of intensity modulated radiation therapy combined with recombinant human p53 adenovirus injection on middle-late type giant piece of cervical carcinoma. Anhui Med J 2015; 36: 19-22.
[13]
Huh JJ, Wolf JK, Fightmaster DL, Lotan R, Follen M. Transduction of adenovirus-mediated wild-type p53 after radiotherapy in human cervical cancer cells. Gynecol Oncol 2003; 89(2): 243-50.
[http://dx.doi.org/10.1016/S0090-8258(03)00054-4] [PMID: 12713987]
[14]
Xia Y, Du Z, Wang X, Li X. Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy. Hum Gene Ther 2018; 29(2): 242-50.
[http://dx.doi.org/10.1089/hum.2017.206] [PMID: 29281902]
[15]
Cross B, Chen L, Cheng Q, Li B, Yuan ZM, Chen J. Inhibition of p53 DNA binding function by the MDM2 protein acidic domain. J Biol Chem 2011; 286(18): 16018-29.
[http://dx.doi.org/10.1074/jbc.M111.228981] [PMID: 21454483]
[16]
Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70(6): 923-35.
[http://dx.doi.org/10.1016/0092-8674(92)90243-6] [PMID: 1356076]
[17]
Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70(6): 937-48.
[http://dx.doi.org/10.1016/0092-8674(92)90244-7] [PMID: 1525830]
[18]
Pappas K, Xu J, Zairis S, et al. p53 Maintains baseline expression of multiple tumor suppressor genes. Mol Cancer Res 2017; 15(8): 1051-62.
[http://dx.doi.org/10.1158/1541-7786.MCR-17-0089] [PMID: 28483946]
[19]
Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. Trends Pharmacol Sci 2004; 25(4): 177-81.
[http://dx.doi.org/10.1016/j.tips.2004.02.009] [PMID: 15116721]
[20]
Xi D, Wang M, Ye H, Luo X, Ning Q. Combined adenovirus-mediated artificial microRNAs targeting mfgl2, mFas, and mTNFR1 protect against fulminant hepatic failure in mice. PLoS One 2013; 8(11)e82330
[http://dx.doi.org/10.1371/journal.pone.0082330] [PMID: 24303082]
[21]
Gai XD, Li GL, Huang JZ, Xue HJ, Wang D. Reversal of multidrug resistance of human hepatocellular carcinoma cells by wild-type p53 gene and related mechanisms. Chin J Cancer 2006; 25(8): 954-9.
[PMID: 16965674]
[22]
Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11(4): 265-83.
[http://dx.doi.org/10.1016/S0928-0987(00)00114-7] [PMID: 11033070]
[23]
Qi X, Chang Z, Song J, Gao G, Shen Z. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin. Anticancer Drugs 2011; 22(6): 556-62.
[http://dx.doi.org/10.1097/CAD.0b013e328345b4e7] [PMID: 21637162]
[24]
Lee YS, Yoon S, Park MS, Kim JH, Lee JH, Song CW. Influence of p53 expression on sensitivity of cancer cells to bleomycin. J Biochem Mol Toxicol 2010; 24(4): 260-9.
[http://dx.doi.org/10.1002/jbt.20334] [PMID: 20135637]
[25]
Guntur VP, Waldrep JC, Guo JJ, Selting K, Dhand R. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res 2010; 30(9): 3557-64.
[PMID: 20944137]
[26]
Liu Q, Sui R, Li R, Miao J, Liu J. Biological characteristics of Taxol resistant ovarian cancer cells and reversal of Taxol resistance by adenovirus expressing p53. Mol Med Rep 2015; 11(2): 1292-7.
[http://dx.doi.org/10.3892/mmr.2014.2784] [PMID: 25351378]
[27]
Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 2013; 13(4): 273-82.
[http://dx.doi.org/10.1038/nrc3432] [PMID: 23426401]
[28]
Fujimoto J, Sakaguchi H, Aoki I, Khatun S, Tamaya T. Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br J Cancer 2001; 85(3): 313-6.
[http://dx.doi.org/10.1054/bjoc.2001.1933] [PMID: 11487257]
[29]
Shibuya M, Luo JC, Toyoda M, Yamaguchi S. Involvement of VEGF and its receptors in ascites tumor formation. Cancer Chemother Pharmacol 1999; 43: S72-7.
[http://dx.doi.org/10.1007/s002800051102] [PMID: 10357563]
[30]
Bekes I, Friedl TWP, Köhler T, et al. Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer? Mol Cancer 2016; 15(15): 13.
[http://dx.doi.org/10.1186/s12943-016-0497-3] [PMID: 26868378]
[31]
Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 2001; 61(18): 6952-7.
[PMID: 11559575]

Rights & Permissions Print Cite
Article Metrics
30
1
© 2024 Bentham Science Publishers | Privacy Policy